X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10189) 10189
Publication (926) 926
Book Review (681) 681
Newsletter (597) 597
Book Chapter (29) 29
Conference Proceeding (22) 22
Dissertation (4) 4
Magazine Article (4) 4
Newspaper Article (3) 3
Paper (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9667) 9667
animals (6907) 6907
male (4937) 4937
humans (4871) 4871
oligopeptides - pharmacology (4656) 4656
rats (3053) 3053
mice (2839) 2839
oligopeptides - administration & dosage (2743) 2743
female (2685) 2685
pharmacology & pharmacy (2116) 2116
oligopeptides - therapeutic use (1673) 1673
oligopeptides - chemistry (1616) 1616
peptides (1448) 1448
oligopeptides (1171) 1171
dose-response relationship, drug (1169) 1169
biochemistry & molecular biology (1078) 1078
adult (1065) 1065
oligopeptides - metabolism (1046) 1046
middle aged (1041) 1041
rats, sprague-dawley (1019) 1019
research (941) 941
neurosciences (874) 874
amino acid sequence (812) 812
cell line, tumor (752) 752
oligopeptides - pharmacokinetics (750) 750
time factors (747) 747
rats, wistar (739) 739
analysis (726) 726
disease models, animal (702) 702
endocrinology & metabolism (696) 696
oligopeptides - adverse effects (682) 682
expression (673) 673
abridged index medicus (642) 642
aged (623) 623
cancer (613) 613
oncology (612) 612
treatment outcome (605) 605
mice, inbred c57bl (578) 578
molecular sequence data (558) 558
article (532) 532
in-vivo (529) 529
drug therapy, combination (528) 528
immunology (528) 528
cells (514) 514
proteins (512) 512
cells, cultured (511) 511
apoptosis (509) 509
in-vitro (501) 501
atazanavir sulfate (497) 497
mice, inbred balb c (494) 494
therapy (464) 464
medicine, research & experimental (461) 461
rat (461) 461
cell biology (459) 459
brain (456) 456
drug delivery systems (453) 453
peptide (445) 445
health aspects (440) 440
oligopeptides - chemical synthesis (428) 428
receptor (428) 428
physiological aspects (425) 425
hiv infections - drug therapy (416) 416
physiology (416) 416
in vitro techniques (407) 407
chemistry, multidisciplinary (397) 397
blood pressure - drug effects (394) 394
care and treatment (394) 394
inflammation (390) 390
injections, intraventricular (365) 365
mice, nude (364) 364
cell line (362) 362
apoptosis - drug effects (360) 360
structure-activity relationship (360) 360
nanoparticles (358) 358
drug therapy (351) 351
infectious diseases (343) 343
hepatitis c, chronic - drug therapy (342) 342
kinetics (342) 342
drugs (341) 341
rodents (341) 341
inhibition (338) 338
activation (336) 336
tumors (336) 336
hematology (321) 321
antiviral agents - therapeutic use (319) 319
drug interactions (318) 318
protease inhibitors (317) 317
oligopeptides - immunology (310) 310
proline - analogs & derivatives (309) 309
pyridines - administration & dosage (309) 309
gastroenterology & hepatology (306) 306
morphine (299) 299
receptors (299) 299
multidisciplinary sciences (293) 293
medicine (292) 292
gene expression (291) 291
cell survival - drug effects (289) 289
rats, inbred strains (287) 287
tissue distribution (287) 287
rabbits (286) 286
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10420) 10420
Russian (188) 188
German (45) 45
Japanese (44) 44
Chinese (30) 30
Spanish (28) 28
French (24) 24
Hungarian (7) 7
Polish (3) 3
Slovak (3) 3
Czech (2) 2
Danish (2) 2
Hebrew (2) 2
Ukrainian (2) 2
Croatian (1) 1
Finnish (1) 1
Italian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2012, Volume 161, Issue 3, pp. 735 - 745
The objective of the present study was to investigate the effect of polyarginine chain length on topical delivery of surface modified NLCs. Design of... 
Nanostructured lipid carriers (NLC) | Cell penetrating peptide (CPP) | Polyarginine peptide | Skin delivery | Allergic contact dermatitis (ACD) | DRUG-DELIVERY | CHITOSAN CROSS-LINKING | TRANSDERMAL DELIVERY | MEFLOQUINE HYDROCHLORIDE MICROPARTICLES | CELL-PENETRATING PEPTIDES | TACROLIMUS OINTMENT | CHEMISTRY, MULTIDISCIPLINARY | DERMAL DELIVERY | PHARMACOLOGY & PHARMACY | H-II MESOPHASES | SUBSTANCE-P | SPANTIDE-II | Nanoparticles - chemistry | Drug Carriers - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Drug Carriers - chemistry | Peptides - administration & dosage | Ketoprofen - chemistry | Allergens - administration & dosage | Lipids - chemistry | Rats, Hairless | Skin Absorption - drug effects | Substance P - analogs & derivatives | Oligopeptides - chemistry | Cell-Penetrating Peptides - chemistry | Dermatitis, Allergic Contact - drug therapy | Peptides - chemistry | Mice, Inbred C57BL | Ketoprofen - administration & dosage | Rats | Lipids - administration & dosage | Dinitrofluorobenzene - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Mice | Nanoparticles - administration & dosage | Oligopeptides - administration & dosage | Cell-Penetrating Peptides - administration & dosage | Administration, Topical | Substance P - chemistry | Substance P - administration & dosage | Usage | Peptides | Dermatology | Analysis | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Raman spectroscopy | Transdermal medication | Index Medicus | polyarginine peptide | cell penetrating peptide (CPP) | nanostructured lipid carriers (NLC) | allergic contact dermatitis (ACD)
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
BACKGROUND:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal... 
CASTLE study | HIV-1 | Combination antiretroviral therapy | Atazanavir/ritonavir | Treatment-naive patients | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | ADULTS | IMMUNOLOGY | REGIMENS | ADHERENCE | HIV-INFECTED PATIENTS | THERAPY | DIDANOSINE | EFAVIRENZ | DRUGS | atazanavir/ritonavir | SAQUINAVIR/RITONAVIR | combination antiretroviral therapy | treatment-naive patients | Humans | Middle Aged | Male | RNA, Viral - blood | Oligopeptides - adverse effects | Viral Load | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | HIV-1 - isolation & purification | Lipids - blood | Aged, 80 and over | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Antiretroviral Therapy, Highly Active - methods | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Drug therapy | Ribonucleic acid--RNA | Human immunodeficiency virus--HIV | Index Medicus | AIDS/HIV
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 06/2016, Volume 232, pp. 20 - 28
Low efficacy of cationic polymer-based formulations (polyplexes) for systemic gene delivery to tumors remains the crucial concern for their clinical... 
Gene delivery | Polyplexes | Nanoparticle extravasation | Tumor uptake | Tumor vasculature | SOLID TUMORS | ANGIOTENSIN-II | VASCULAR-PERMEABILITY | MALIGNANT-MELANOMA | CHEMISTRY, MULTIDISCIPLINARY | TRANSFECTION EFFICACY | INDUCED HYPERTENSION | ENHANCED PERMEABILITY | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | NONVIRAL VECTORS | Angiotensin II - administration & dosage | Vasodilator Agents - pharmacokinetics | Gene Expression Regulation, Neoplastic | Melanoma, Experimental - metabolism | Green Fluorescent Proteins - genetics | Receptor, Melanocortin, Type 1 - metabolism | Nitroglycerin - pharmacology | Drug Delivery Systems | Polyethyleneimine - pharmacokinetics | Melanoma, Experimental - physiopathology | Regional Blood Flow - drug effects | Nitroglycerin - pharmacokinetics | Nitroglycerin - administration & dosage | Female | Mice, Inbred DBA | Losartan - pharmacokinetics | Polyethylene Glycols - pharmacology | Vasoconstrictor Agents - pharmacology | Gene Transfer Techniques | Angiotensin II - pharmacology | Vasoconstrictor Agents - administration & dosage | Vasoconstrictor Agents - pharmacokinetics | Collagen Type I - metabolism | Vasodilator Agents - pharmacology | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Oligopeptides - pharmacokinetics | Losartan - pharmacology | DNA - administration & dosage | Polyethylene Glycols - pharmacokinetics | Polyethyleneimine - pharmacology | Angiotensin II - pharmacokinetics | Polyethylene Glycols - administration & dosage | Polyethyleneimine - analogs & derivatives | Administration, Intravenous | Animals | Melanoma, Experimental - genetics | Polyethyleneimine - administration & dosage | Cell Line, Tumor | Luciferases, Firefly - genetics | Nanoparticles - administration & dosage | Oligopeptides - administration & dosage | Losartan - administration & dosage | Vasodilator Agents - administration & dosage | Nitrates | Drug therapy | Nitroglycerin | Tumors | Molecular genetics | Melanoma | Angiotensin | Research institutes | Index Medicus
Journal Article
Journal Article